N/A N=40 Effect of Premeal Protein-bar on Glycemic Control in Patients With Type 2 Diabetes
Patients With Type 2 Diabetes
Primary: Change in HbA1c From Baseline — 0.015; 0.030 % (HbA1c) — p=0.933
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=93 Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism
Hyperthyroidism · Hypothyroidism
Primary: Thyroid Extreme CT — 0.89; 1.16 mm
Early Phase 1 N=70 Comparison of Chloroprocaine vs Lidocaine for Epidural Anesthesia in Cesarean Delivery
Surgical Anesthesia, Cesarean Section
Primary: The Onset Time to Surgical Anesthesia — 558; 655 seconds — p=0.10
N/A N=59 Corneal Biomechanics and Corneal Reshaping Therapy
Myopia
Primary: Change of Corneal Stiffness From Baseline at 6 Months — 0.061 N/mm
N/A N=10 Transcranial Magnetic Stimulation for Children With Tourette's Syndrome
Tourette Syndrome
Primary: Yale Global Tic Severity Scale — 64.40; 26.40 units on a scale
Phase 2 N=22 Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer
Breast Neoplasms
Primary: Number of Participants With Adverse Events — 8; 7; 6; 5 Participants
N/A N=48 Trans-incisional vs Laparoscopic Guided Rectus Sheath Block for Pediatric Single Incision Laparoscopic Cholecystectomy
Pain, Postoperative
Primary: Post Operative Pain Rating — 4.03; 4.03 score on a scale
N/A N=17 Spinal Cord Stimulation to Restore Cough
Spinal Cord Injuries · Spinal Cord Diseases · Paralysis
Primary: Effectiveness of Expiratory Muscle Activation to Generate Large Airway Pressures Characteristic of Normal Cough. — 25; 121 cmH2O — p=<0.05
Phase 1 N=88 Phase I, KM-819 in Healthy Subjects for Parkinson's Disease
Parkinson's Disease
Primary: Number of Participants With Adverse Events — 2; 2; 2; 1 participants
Phase 1 N=40 Phase 1 Study of PBTZ169
Tuberculosis
Primary: Incidence of Drug-related Adverse Events [Safety and Tolerability] — 2; 2; 1; 0 participants
Phase 1 N=36 Improving Functional Outcomes of Veterans With PTSD and Tobacco Dependence
Tobacco · Posttraumatic Stress Disorder
Primary: 7-day Point Prevalence of Smoking Abstinence — 4; 0 Participants
Phase 4 N=33 Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome
Stable Angina · Metabolic Syndrome
Primary: Impact of Ranolazine on Hemoglobin A1C — -5; 2.6 percent change
N/A N=1,057 Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR)
Rheumatoid Arthritis
Primary: Percentage of Participants Who Met All Effectiveness Criteria up to 12 Months From the Index Date — 33.33; 25.86 percentage of participants — p=0.0115
N/A N=657 LEVANT 2 Continuation Registry of the Lutonix® Drug Coated Balloon (DCB)
Peripheral Artery Disease
Primary: Number of Unanticipated Device- or Drug- Related Adverse Events Through 60 Months Post Index Procedure — 0 Events
Phase 3 N=283 A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
Post-Menopausal Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine BMD at Month 6 — 9.2; 9.0 percent change — p=0.84